News about Market

Solventum to Acquire Acera Surgical for USD 725 Million to Boost Regenerative Wound Care

Solventum, a healthcare company rooted in decades of innovation, announced a definitive agreement to acquire Acera Surgical for $725 million in cash, with an additional $125 million in milestone-based contingent payments.

Market | 21/11/2025 | By Darshana |  293

Abbott to Acquire Exact Sciences in USD 21 Billion Deal, Entering Cancer Diagnostics Sectors

After the transaction, Exact Sciences—projected to generate more than USD 3 billion in revenue this year with high-teens organic growth—will operate as a subsidiary of Abbott.

Market | 21/11/2025 | By Dineshwori |  292

GSK and LTZ Collaborate to Advance Novel Myeloid Cell Engagers in Oncology

Leveraging LTZ’s novel immune-engager platform and GSK’s oncology expertise, the partnership aims to deliver potent, safer cancer therapies that can be administered in community settings, supporting GSK’s strategy to advance transformative medicines through cutting-edge technologies.

Market | 20/11/2025 | By Dineshwori |  228

EY-OPPI Report Outlines Three-Pronged Strategy to Unlock India's USD 450 Billion Pharma Potential

India’s pharma industry will need to move from a volume-led approach to a model driven by value, innovation and stronger collaboration across the ecosystem if it is to achieve its projected value of USD 450 billion by 2047, says EY–OPPI Report.

Market | 20/11/2025 | By Dineshwori |  499

Thermo Fisher Opens East Coast Collaboration Center for Advanced Therapeutics

Thermo Fisher Scientific has opened a new East Coast Collaboration Center at BioLabs in Philadelphia, offering advanced lab space and expert support to help researchers accelerate the development of cell and gene therapies from early-stage discovery to clinical readiness.

Market | 19/11/2025 | By Dineshwori |  221

EU Approves Insmed's BRINSUPRI, the First Treatment for Non-CF Bronchiectasis

The European Commission has approved BRINSUPRI as the first treatment for Non-Cystic Fibrosis Bronchiectasis, offering a new option for patients with this serious, progressive lung disease. The first-in-class DPP1 inhibitor was granted accelerated assessment by the EMA, reflecting its significant public health importance.

Market | 19/11/2025 | By Dineshwori |  331

Marksans Pharma Subsidiary Secures USFDA Approval for Loperamide Hydrochloride Tablets USP, 2 mg

Marksans Pharma's wholly owned subsidiary, Marksans Pharma Inc., has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).

Market | 19/11/2025 | By Dineshwori |  198

AbbVie Receives FDA Approval for EPKINLY Combo in Relapsed/Refractory Follicular Lymphoma

AbbVie has secured FDA approval for EPKINLY in combination with rituximab and lenalidomide (EPKINLY + R2), marking the first bispecific antibody combo therapy available for patients with relapsed or refractory follicular lymphoma after at least one prior systemic treatment.

Market | 19/11/2025 | By Dineshwori |  262

Johnson & Johnson to Acquire Halda Therapeutics for USD 3.05 Billion

Johnson & Johnson has struck a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotech company, for USD 3.05 billion in cash. Halda is known for its proprietary RIPTAC™ platform, which enables the development of oral, precision cancer therapies.

Market | 18/11/2025 | By Darshana |  208

Marksans Pharma's UK Arm Relonchem Receives UK MHRA Approval for Mefenamic Acid Tablets

Marksans Pharma announced that its wholly owned UK subsidiary, Relonchem, has received marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for mefenamic acid 250 mg and 500 mg film-coated tablets. The approval further expands Relonchem’s growing footprint in the UK generics market.

Market | 17/11/2025 | By Dineshwori |  412